Late Breaking Abstract - Benralizumab treatment strongly reduces blood basophils in patients with severe eosinophilic asthma

Conclusion: Benralizumab treatment strongly reduces basophils in patients with severe asthma, suggesting that the effects of Benralizumab in severe asthma might not be restricted to the depletion of eosinophils. Funding: This investigator-initiated study was funded by AstraZeneca (ESR-16-124 73).

Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: Marchewski, H., Bratke, K., Schwefel, G., Virchow, J. C., Lommatzsch, M. Tags: Allergy and immunology Source Type: research